Texas
LATEST FROM BIOSPACE
More than 103,000 people in the U.S. were hospitalized on January 3, 2022, for COVID-19—the highest daily figure of hospitalizations since last summer when the Delta variant emerged.
Low-income countries still struggle to get first jabs into arms. Researchers and pharma companies continue to push for low-cost vaccines and drugs worldwide.
The year kicked off with a bang as multiple companies raced to a public listing.
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
The 2021 San Antonio Breast Cancer Symposium is meeting December 7–10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, and virtually.
Shares of Reata Pharmaceuticals have plunged nearly 40% in premarket trading after an FDA advisory panel recommended against the approval of its Alport syndrome disease treatment, bardoxolone.
Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for its Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D).
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES